Developer docs
API playgroundTry for free, no card

Search company profiles

SMi Systems

Full company profile

uuid0002ljo

Namestring
SMi Systems
Legal namestring
SMi Drug Discovery Limited
Company typeenum
Private
Founded yearint
2018
Descriptiontext

SMi Systems (trading as SMi Drug Discovery Limited) is a UK-headquartered biomedical instrumentation company founded in 2018 that has developed an automated benchtop single-molecule imaging platform. The platform integrates three components into a single workflow: a super-resolution optical instrument capable of imaging at approximately 1.6 nanometre resolution across a large field of view, proprietary consumable sensor chips in standard 96- and 384-well microarray formats, and TALoS® — trademarked proprietary software using AI/deep-learning algorithms to automate detection, counting, and quantification of individual molecules (the SWiFT® trademark covers SMi's underlying experimental approach). The system is configured into two principal go-to-market offerings: a Biomedical Research Platform targeting drug-discovery and screening workflows, and a Multi-omic Diagnostic Platform positioned for hospitals and reference laboratories.

SMi generates revenue through a mix of instrument sales, recurring consumables (chips), fee-for-service contract R&D with biopharma customers (including two top-20 pharma R&D contracts in Q4 2023 and Q1 2025), and non-dilutive grant funding from Innovate UK and other UK bodies. The company employs 11–50 staff across its UK headquarters in Cambridge and US R&D laboratories in Washington State, and has built a partner-enabled commercialisation stack using Cogent Technology Ltd for contract manufacturing, the National Physical Laboratory for measurement validation, Medicines Discovery Catapult and the University of Cambridge for translational research, and most recently Luminex Corporation for diagnostic-platform integration.

The company sells directly to enterprise biopharma and diagnostic customers through a contact-led model supplemented by conference presence (BPS, EMMD, Pharma Industry Awards UK) and co-marketing with technology vendors such as Teledyne Photometrics. Pricing is quote-based and not publicly disclosed. SMi has secured granted patents in the UK, Hong Kong, the US, and Singapore, achieved ISO 13485 medical-device certification (June 2025) with UKCA/CE marking (Q2 2023), and closed a third major equity round in December 2025 alongside prior seed funding of £6 million led by Norcliffe Capital in June 2023.

Short descriptiontext

SMi Systems develops an automated benchtop single-molecule imaging platform combining a 1.6 nm-resolution optical instrument, 96/384-well consumable chips, and proprietary AI software (TALoS®) for biomedical research and in-vitro diagnostics, serving biopharma companies, diagnostic developers, and reference laboratories.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
single-molecule imaging, benchtop imaging instruments, in-vitro diagnostics, biomedical research platforms, consumable microarray chips
Product category
Single-Molecule Imaging Instruments
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model4 records
1Instrument sales
TypeHardware Sales
Description

Sale of SMi's benchtop super-resolution single molecule imaging instruments (manufactured via Cogent Technology Ltd contract manufacturing). One-time hardware revenue per instrument placement, including early-access placements to research and pharma customers.

smisystems.co.uk
2Consumables (sensor chips)
TypeUsage Based
Description

Recurring revenue from proprietary 96/384-well microarray consumable chips used with the instrument. SMi trials commercial manufacture of consumables (Q2 2024), creating a razor/blade-style recurring revenue stream alongside instrument placements.

smisystems.co.uk
3Contract research / R&D services
TypeProfessional Services
Description

Fee-for-service R&D contracts with biopharma and diagnostics customers. Began with first external R&D project with a top-20 pharma company (Q4 2023), expanded to a second R&D contract with a top-20 pharma company (Q1 2025), and a new R&D project with a global diagnostic developer (Q1 2026). Examples include novel quality control assays for biologics production and infectious particle detection.

smisystems.co.uk
4Non-dilutive grant funding
TypeManaged Services
Description

Grant income from Innovate UK (£1.9M in 2021 plus additional awards in 2022), CPI, and Suffolk County Council's Suffolk Economy Grant. Supports R&D and regulatory work but is funding rather than commercial revenue.

smisystems.co.uk
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1TALoS®
Description

Proprietary single molecule detection software trademarked by SMi in Q1 2024.

smisystems.co.uk
+1 more record
Core offering1 text field

SMi Systems develops, manufactures and sells an integrated, automated benchtop single-molecule imaging platform that combines a proprietary super-resolution optical instrument, consumable 96- and 384-well microarray sensor chips, and the trademarked TALoS® AI/deep-learning software. The platform is offered to biopharma, hospitals/reference diagnostic laboratories, and academic institutions for biomedical research, drug discovery, and in-vitro diagnostics, delivering 1.6-nanometre resolution detection of DNA, RNA, protein and inorganic molecules across hundreds of thousands of molecules per run.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Detection in less than a second per sample; up to 384 samples processed in minutes
+5 more records
Product overview1 text field

SMi Systems (trading as SMi Drug Discovery Limited) offers a single unified single-molecule imaging platform rather than a collection of standalone products. The core offering — branded simply as the SMi Single Molecule Imaging Platform — is a platform-plus-modules architecture comprising three tightly integrated components: the SMi Benchtop Instrument (hardware), SMi Consumables in 96- and 384-well formats (proprietary optical chips), and TALoS® software (the trademarked, proprietary single-molecule detection and analysis engine). These three components are delivered as one automated workflow for both biomedical research and in-vitro diagnostic applications, with two principal go-to-market configurations: the Biomedical Research Platform (for drug discovery and screening) and the Multi-omic Diagnostic Platform (for hospitals and reference laboratories). SMi's novel experimental approach, SWiFT®, is trademarked as a methodology underpinning the platform.

Product and service6 records
1SMi Single Molecule Imaging Platform
CategoryCore platform
2SMi Benchtop Instrument
CategoryHardware component
3SMi Consumables (96 / 384-well Optical Chips)
CategoryHardware component
4SMi Multi-omic Diagnostic Platform
CategoryVertical solution - Diagnostics
5SMi Biomedical Research Platform
CategoryVertical solution - Drug Discovery
6SMi Contract Research Services
CategoryProfessional services - Contract Research
Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierFlagshipTypeTechnology or IntegrationAnnounced on2026-06-02
Description

Non-exclusive evaluation collaboration announced 2 June 2026 to assess the feasibility of using Luminex beads with SMi's single-molecule imaging platform and compare analytical sensitivity against Luminex's existing xMAP readers under defined test conditions. Initial phase focuses on research activities to validate whether SMi's technology can complement Luminex's industry-leading xMAP technology, targeting the $1.8 billion global multiplex assay market.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

MDC has worked with SMi since its early days as a small start-up. SMi developed its early-generation instruments at the US facility and later installed one in MDC's state-of-the-art laboratory facilities at Alderley Park, Cheshire. The partnership has continued to grow through competitive Innovate UK awards to apply SMi's technology to infectious diseases and cancer diagnosis. MDC also presents SMi-related findings (e.g., at the 13th EMMD Conference, Oct 2024).

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

The University of Cambridge has been integral to SMi's success, with early-generation instruments undergoing testing in Professor Ravindra Gupta's labs in the Department of Medicine. Partnering with an academic group has allowed SMi to think beyond commercial constraints and find ways to answer more general questions relating to disease.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

SMi has worked with NPL — the UK's national measurement institute responsible for developing and maintaining national primary measurement standards — to validate experimental results from all its other activities and to ensure it is a leader in the measurement of single molecules.

5Medical Devices Testing & Evaluation Centre (MD-TEC)
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

MD-TEC, based at University Hospitals Birmingham NHS Foundation Trust, has supported SMi's objectives to create a platform that is accessible to all abilities and experience. SMi completed its first formal usability tests there in October 2022.

smisystems.co.uk
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Cogent offers SMi world-class facilities, cutting-edge technologies and the highest regulatory and quality standards to ensure that the SMi platform complies with required manufacturing quality standards and can meet the needs of both medical and research communities. Q1 2023: SMi worked with Cogent to integrate quality management systems and create the first contract-manufactured instruments.

Strategic tierCoreTypeTechnology or Integration
Description

Teledyne Photometrics imaging systems are integrated into SMi's products, as described in a joint case study published 24 November 2025 describing how SMi and Teledyne Photometrics are revolutionizing diagnostics throughput.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing Partner
Description

Knight Optical worked with SMi's engineers to develop custom optics for volume manufacture; documented in a commercial R&D case study published 11 September 2025.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

SMi worked with ProPharma to build an ISO 13485 Quality Management System that ensures compliance to rigorous medical device standards; ProPharma documented the engagement in a case study published 25 September 2024.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Batalas featured how their internal audit training course helped SMi work towards ISO 13485:2016 Quality Management System certification (case study published 7 October 2024).

Strategic tierCoreTypeStrategic or Co-development Partner
Description

SMi received an NIHR grant award in February 2022 to fund public and patient engagement studies; SMi also undertook formal usability testing at the NIHR Medical Devices Testing and Evaluation Centre.

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeDirect peer
Description

Quanterix's Simoa® platform is the most commercially advanced bead-based single-molecule immunoassay technology, directly competing with SMi's super-resolution single-molecule detection workflow for ultra-sensitive protein and biomarker measurement in biopharma and clinical diagnostics.

TypeBroad incumbent
Description

Bio-Rad is a broad life-science and clinical diagnostics incumbent explicitly cited by SMi as a competitive pressure point, with Bio-Plex multiplex assay systems and droplet-based digital PCR that overlap with SMi's multiplex and single-molecule use cases.

TypeBroad incumbent
Description

Thermo Fisher is the dominant life-science instruments and diagnostics incumbent, selling ELISA, PCR, SPR and bead-based multiplex workflows that SMi explicitly aims to displace; an ex-Thermo Fisher CMO (Dr David Onions) is also on SMi's investor side, reflecting the strategic overlap.

TypeDirect peer
Description

Luminex's xMAP bead-based multiplex assay platform is both a direct competitor in multiplex diagnostics and SMi's named integration partner (June 2026), targeting the same $1.8B multiplex assay market and biopharma/clinical buyer set.

TypeDirect peer
Description

Meso Scale Diagnostics offers electrochemiluminescence-based multiplex platforms (SECTOR, U-PLEX) for biopharma and clinical biomarker workflows, directly competing with SMi's claim of higher-sensitivity, faster, multiplexed detection on a single benchtop platform.

TypeEmerging player
Description

Quantum-Si is an emerging single-molecule protein sequencing player, overlapping with SMi's multi-omic and single-molecule detection roadmap for proteomics and biomarker discovery, though focused on protein sequencing rather than general single-molecule imaging.

TypeDirect peer
Description

Olink's proximity extension assay technology delivers high-multiplex protein biomarker measurement for biopharma and clinical research, competing for the same proteomics/multi-omic wallet share that SMi's platform targets.

TypeEmerging player
Description

Pacific Biosciences' SMRT sequencing is a single-molecule detection technology used in genomics and transcriptomics, sharing SMi's core single-molecule imaging heritage and biopharma/clinical buyer base, though focused on nucleic acid sequencing rather than multi-omic diagnostics.

TypeEmerging player
Description

Oxford Nanopore performs single-molecule sensing of nucleic acids on a benchtop/portable platform, sharing SMi's single-molecule scientific lineage and selling into research, biopharma and clinical customers, but specialised in nanopore sequencing rather than multi-omic imaging.

10Singulex (EMD MilliporeSigma)
TypeEmerging player
Description

Singulex's single-molecule counting (SMC) immunoassay technology (now part of EMD MilliporeSigma) is a direct technological analogue to SMi's single-molecule detection for ultra-sensitive protein biomarker measurement, serving a similar biopharma and clinical research buyer set.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SMi Systems

Single-Molecule Imaging Instrumentssmisystems.co.uk

SMi Systems develops an automated benchtop single-molecule imaging platform combining a 1.6 nm-resolution optical instrument, 96/384-well consumable chips, and proprietary AI software (TALoS®) for biomedical research and in-vitro diagnostics, serving biopharma companies, diagnostic developers, and reference laboratories.

What SMi Systems does

SMi Systems (trading as SMi Drug Discovery Limited) is a UK-headquartered biomedical instrumentation company founded in 2018 that has developed an automated benchtop single-molecule imaging platform. The platform integrates three components into a single workflow: a super-resolution optical instrument capable of imaging at approximately 1.6 nanometre resolution across a large field of view, proprietary consumable sensor chips in standard 96- and 384-well microarray formats, and TALoS® — trademarked proprietary software using AI/deep-learning algorithms to automate detection, counting, and quantification of individual molecules (the SWiFT® trademark covers SMi's underlying experimental approach). The system is configured into two principal go-to-market offerings: a Biomedical Research Platform targeting drug-discovery and screening workflows, and a Multi-omic Diagnostic Platform positioned for hospitals and reference laboratories.

SMi generates revenue through a mix of instrument sales, recurring consumables (chips), fee-for-service contract R&D with biopharma customers (including two top-20 pharma R&D contracts in Q4 2023 and Q1 2025), and non-dilutive grant funding from Innovate UK and other UK bodies. The company employs 11–50 staff across its UK headquarters in Cambridge and US R&D laboratories in Washington State, and has built a partner-enabled commercialisation stack using Cogent Technology Ltd for contract manufacturing, the National Physical Laboratory for measurement validation, Medicines Discovery Catapult and the University of Cambridge for translational research, and most recently Luminex Corporation for diagnostic-platform integration.

The company sells directly to enterprise biopharma and diagnostic customers through a contact-led model supplemented by conference presence (BPS, EMMD, Pharma Industry Awards UK) and co-marketing with technology vendors such as Teledyne Photometrics. Pricing is quote-based and not publicly disclosed. SMi has secured granted patents in the UK, Hong Kong, the US, and Singapore, achieved ISO 13485 medical-device certification (June 2025) with UKCA/CE marking (Q2 2023), and closed a third major equity round in December 2025 alongside prior seed funding of £6 million led by Norcliffe Capital in June 2023.

SMi Systems firmographics

Firmographics
Name
SMi Systems
Legal name
SMi Drug Discovery Limited
Website
https://smisystems.co.uk
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
SMi Systems develops an automated benchtop single-molecule imaging platform combining a 1.6 nm-resolution optical instrument, 96/384-well consumable chips, and proprietary AI software (TALoS®) for biomedical research and in-vitro diagnostics, serving biopharma companies, diagnostic developers, and reference laboratories.
Ownership category
akta.pro rank

Where SMi Systems is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

SMi Systems business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Instrument sales: Sale of SMi's benchtop super-resolution single molecule imaging instruments (manufactured via Cogent Technology Ltd contract manufacturing). One-time hardware revenue per instrument placement, including early-access placements to research and pharma customers.
  2. Consumables (sensor chips): Recurring revenue from proprietary 96/384-well microarray consumable chips used with the instrument. SMi trials commercial manufacture of consumables (Q2 2024), creating a razor/blade-style recurring revenue stream alongside instrument placements.
  3. Contract research / R&D services: Fee-for-service R&D contracts with biopharma and diagnostics customers. Began with first external R&D project with a top-20 pharma company (Q4 2023), expanded to a second R&D contract with a top-20 pharma company (Q1 2025), and a new R&D project with a global diagnostic developer (Q1 2026). Examples include novel quality control assays for biologics production and infectious particle detection.
  4. Non-dilutive grant funding: Grant income from Innovate UK (£1.9M in 2021 plus additional awards in 2022), CPI, and Suffolk County Council's Suffolk Economy Grant. Supports R&D and regulatory work but is funding rather than commercial revenue.

Go-to-market motion4 records

Distribution channels4 records

Marketing channels6 records

SMi Systems product offering

Product offering

Core offering

SMi Systems develops, manufactures and sells an integrated, automated benchtop single-molecule imaging platform that combines a proprietary super-resolution optical instrument, consumable 96- and 384-well microarray sensor chips, and the trademarked TALoS® AI/deep-learning software. The platform is offered to biopharma, hospitals/reference diagnostic laboratories, and academic institutions for biomedical research, drug discovery, and in-vitro diagnostics, delivering 1.6-nanometre resolution detection of DNA, RNA, protein and inorganic molecules across hundreds of thousands of molecules per run.

Product overview

SMi Systems (trading as SMi Drug Discovery Limited) offers a single unified single-molecule imaging platform rather than a collection of standalone products. The core offering — branded simply as the SMi Single Molecule Imaging Platform — is a platform-plus-modules architecture comprising three tightly integrated components: the SMi Benchtop Instrument (hardware), SMi Consumables in 96- and 384-well formats (proprietary optical chips), and TALoS® software (the trademarked, proprietary single-molecule detection and analysis engine). These three components are delivered as one automated workflow for both biomedical research and in-vitro diagnostic applications, with two principal go-to-market configurations: the Biomedical Research Platform (for drug discovery and screening) and the Multi-omic Diagnostic Platform (for hospitals and reference laboratories). SMi's novel experimental approach, SWiFT®, is trademarked as a methodology underpinning the platform.

Differentiator

Problem solved

Functional benefit

Brands

  • TALoS®: Proprietary single molecule detection software trademarked by SMi in Q1 2024.
  • SWiFT®

Products and services

  • SMi Single Molecule Imaging Platform
  • SMi Benchtop Instrument
  • SMi Consumables (96 / 384-well Optical Chips)
  • SMi Multi-omic Diagnostic Platform
  • SMi Biomedical Research Platform
  • SMi Contract Research Services

Quantifiable outcome

  • Detection in less than a second per sample; up to 384 samples processed in minutes
  • +5 more outcomes

Companies that use SMi Systems

Customer profile

Segments5 records

Ideal customer profiles4 records

SMi Systems technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability6 records

Feature6 records

SMi Systems partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered flagship, core and minor.

  • Luminex CorporationflagshipTechnology or Integration · 2 June 2026Non-exclusive evaluation collaboration announced 2 June 2026 to assess the feasibility of using Luminex beads with SMi's single-molecule imaging platform and compare analytical sensitivity against Luminex's existing xMAP readers under defined test conditions. Initial phase focuses on research activities to validate whether SMi's technology can complement Luminex's industry-leading xMAP technology, targeting the $1.8 billion global multiplex assay market.
  • Medicines Discovery Catapult (MDC)flagshipStrategic or Co-development PartnerMDC has worked with SMi since its early days as a small start-up. SMi developed its early-generation instruments at the US facility and later installed one in MDC's state-of-the-art laboratory facilities at Alderley Park, Cheshire. The partnership has continued to grow through competitive Innovate UK awards to apply SMi's technology to infectious diseases and cancer diagnosis. MDC also presents SMi-related findings (e.g., at the 13th EMMD Conference, Oct 2024).
  • University of CambridgeflagshipStrategic or Co-development PartnerThe University of Cambridge has been integral to SMi's success, with early-generation instruments undergoing testing in Professor Ravindra Gupta's labs in the Department of Medicine. Partnering with an academic group has allowed SMi to think beyond commercial constraints and find ways to answer more general questions relating to disease.
  • National Physical Laboratory (NPL)coreStrategic or Co-development PartnerSMi has worked with NPL — the UK's national measurement institute responsible for developing and maintaining national primary measurement standards — to validate experimental results from all its other activities and to ensure it is a leader in the measurement of single molecules.
  • Medical Devices Testing & Evaluation Centre (MD-TEC)coreImplementation/ SI/ Consulting PartnerMD-TEC, based at University Hospitals Birmingham NHS Foundation Trust, has supported SMi's objectives to create a platform that is accessible to all abilities and experience. SMi completed its first formal usability tests there in October 2022.
  • Cogent Technology LtdcoreImplementation/ SI/ Consulting PartnerCogent offers SMi world-class facilities, cutting-edge technologies and the highest regulatory and quality standards to ensure that the SMi platform complies with required manufacturing quality standards and can meet the needs of both medical and research communities. Q1 2023: SMi worked with Cogent to integrate quality management systems and create the first contract-manufactured instruments.
  • Teledyne PhotometricscoreTechnology or IntegrationTeledyne Photometrics imaging systems are integrated into SMi's products, as described in a joint case study published 24 November 2025 describing how SMi and Teledyne Photometrics are revolutionizing diagnostics throughput.
  • Knight OpticalminorOEM/ Whitelabel/ Licensing PartnerKnight Optical worked with SMi's engineers to develop custom optics for volume manufacture; documented in a commercial R&D case study published 11 September 2025.
  • ProPharma GroupcoreImplementation/ SI/ Consulting PartnerSMi worked with ProPharma to build an ISO 13485 Quality Management System that ensures compliance to rigorous medical device standards; ProPharma documented the engagement in a case study published 25 September 2024.
  • BatalasminorImplementation/ SI/ Consulting PartnerBatalas featured how their internal audit training course helped SMi work towards ISO 13485:2016 Quality Management System certification (case study published 7 October 2024).
  • NIHR (National Institute for Health and Care Research)coreStrategic or Co-development PartnerSMi received an NIHR grant award in February 2022 to fund public and patient engagement studies; SMi also undertook formal usability testing at the NIHR Medical Devices Testing and Evaluation Centre.

Scale indicators13 records

Recent moves2 records

SMi Systems competitors and assessment

Company assessment

Direct peers

  • Quanterix: Quanterix's Simoa® platform is the most commercially advanced bead-based single-molecule immunoassay technology, directly competing with SMi's super-resolution single-molecule detection workflow for ultra-sensitive protein and biomarker measurement in biopharma and clinical diagnostics.
  • Luminex Corporation (DiaSorin): Luminex's xMAP bead-based multiplex assay platform is both a direct competitor in multiplex diagnostics and SMi's named integration partner (June 2026), targeting the same $1.8B multiplex assay market and biopharma/clinical buyer set.
  • Meso Scale Diagnostics: Meso Scale Diagnostics offers electrochemiluminescence-based multiplex platforms (SECTOR, U-PLEX) for biopharma and clinical biomarker workflows, directly competing with SMi's claim of higher-sensitivity, faster, multiplexed detection on a single benchtop platform.
  • Olink: Olink's proximity extension assay technology delivers high-multiplex protein biomarker measurement for biopharma and clinical research, competing for the same proteomics/multi-omic wallet share that SMi's platform targets.

Broad incumbents

  • Bio-Rad Laboratories: Bio-Rad is a broad life-science and clinical diagnostics incumbent explicitly cited by SMi as a competitive pressure point, with Bio-Plex multiplex assay systems and droplet-based digital PCR that overlap with SMi's multiplex and single-molecule use cases.
  • Thermo Fisher Scientific: Thermo Fisher is the dominant life-science instruments and diagnostics incumbent, selling ELISA, PCR, SPR and bead-based multiplex workflows that SMi explicitly aims to displace; an ex-Thermo Fisher CMO (Dr David Onions) is also on SMi's investor side, reflecting the strategic overlap.

Emerging players

  • Quantum-Si: Quantum-Si is an emerging single-molecule protein sequencing player, overlapping with SMi's multi-omic and single-molecule detection roadmap for proteomics and biomarker discovery, though focused on protein sequencing rather than general single-molecule imaging.
  • Pacific Biosciences: Pacific Biosciences' SMRT sequencing is a single-molecule detection technology used in genomics and transcriptomics, sharing SMi's core single-molecule imaging heritage and biopharma/clinical buyer base, though focused on nucleic acid sequencing rather than multi-omic diagnostics.
  • Oxford Nanopore Technologies: Oxford Nanopore performs single-molecule sensing of nucleic acids on a benchtop/portable platform, sharing SMi's single-molecule scientific lineage and selling into research, biopharma and clinical customers, but specialised in nanopore sequencing rather than multi-omic imaging.
  • Singulex (EMD MilliporeSigma): Singulex's single-molecule counting (SMC) immunoassay technology (now part of EMD MilliporeSigma) is a direct technological analogue to SMi's single-molecule detection for ultra-sensitive protein biomarker measurement, serving a similar biopharma and clinical research buyer set.

Market position

Strengths5 records

Weaknesses5 records

Key risks7 records

Key highlights7 records

Customer concentration

SMi Systems social profiles

Digital presence

SMi Systems compliance and trust

Trust signal

Compliance2 records

SMi Systems financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SMi Systems leadership team

Management profile

Number of profiles

Profiles9 records

SMi Systems funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SMi Systems M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SMi Systems

What does SMi Systems do?

SMi Systems develops, manufactures and sells an integrated, automated benchtop single-molecule imaging platform that combines a proprietary super-resolution optical instrument, consumable 96- and 384-well microarray sensor chips, and the trademarked TALoS® AI/deep-learning software. The platform is offered to biopharma, hospitals/reference diagnostic laboratories, and academic institutions for biomedical research, drug discovery, and in-vitro diagnostics, delivering 1.6-nanometre resolution detection of DNA, RNA, protein and inorganic molecules across hundreds of thousands of molecules per run.

Is SMi Systems a public or private company?

SMi Systems is a private company. It is classified as venture growth investor backed and is currently operating.

When was SMi Systems founded?

SMi Systems was founded in 2018. It employs 11 to 50 people.

Where is SMi Systems based?

SMi Systems is headquartered in Cambridge, United Kingdom, in the Europe region.

How does SMi Systems make money?

Four revenue lines are on record. Instrument sales are the primary driver. The others are consumables (sensor chips), contract research / R&D services and non-dilutive grant funding.

Who are SMi Systems's main competitors?

Direct peers on record are Quanterix, Luminex Corporation (DiaSorin), Meso Scale Diagnostics and Olink. Broad incumbents are Bio-Rad Laboratories and Thermo Fisher Scientific. Emerging players are Quantum-Si, Pacific Biosciences, Oxford Nanopore Technologies and Singulex (EMD MilliporeSigma).

Does SMi Systems have an API?

No public API is recorded for SMi Systems.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceSMi Systems announces a non-exclusive collaboration with LuminexSMi Systems has entered into a non-exclusive evaluation collaboration with Luminex Corporation to assess whether SMi's single-molecule imaging platform can work alongside Luminex's xMAP technology. The partnership will involve testing Luminex beads with SMi's platform and comparing analytical sensitivity against Luminex's current xMAP readers. The evaluation is initially focused on research activities to validate the potential complementarity of the two technologies.BriefglanceSMi Systems and Luminex: A Partnership to See the Unseen in DiagnosticsUK/US-based SMi Systems has announced a non-exclusive evaluation collaboration with Luminex Corporation to test whether SMi's high-sensitivity single-molecule imaging platform can enhance Luminex's industry-standard xMAP bead technology for multiplex diagnostics. The partnership targets the $1.8 billion global multiplex assay market, projected to more than double by 2030, with Luminex seeking to maintain competitive edge against rivals like Bio-Rad and Thermo Fisher Scientific while SMi, which achieved ISO 13485 certification in June 2025, pursues validation from an established industry leader. If successful, the integration of SMi's 1.6-nanometer resolution imaging with Luminex's capacity to measure up to 500 analytes simultaneously could enable earlier disease detection in oncology, immunology, and vaccine development.PR NewswireSMi Systems announces a non-exclusive collaboration with LuminexSMi Systems announced a non-exclusive evaluation collaboration with Luminex Corporation to assess the feasibility of using Luminex beads with SMi's single-molecule imaging platform and compare analytical sensitivity against Luminex's existing xMAP readers under defined test conditions. The initial phase will focus on research activities to validate whether SMi's technology can complement Luminex's industry-leading xMAP technology.PR NewswireSMi Systems Appoints Ronnie Andrews of Bethesda Group Advisors as Non-Executive DirectorSMi Systems, a UK/US life science technology company specializing in single-molecule detection for drug discovery and diagnostics, has appointed Ron Andrews to its Board of Directors as a Non-Executive Director. Andrews brings over 35 years of strategic leadership experience in the Life Sciences Tools and Molecular Diagnostics sectors, having previously held executive roles at companies including Abbott Diagnostics, Roche Molecular Diagnostics, and Thermo Fisher, as well as CEO positions at Clarient Inc and Oncocyte Inc. The company stated that Andrews' appointment supports its preparation for market entry and underscores its commitment to building a world-class leadership team.Drug Discovery World (DDW)SMi discloses £6 million seed funding roundSMi Systems has secured a £6 million seed funding round to develop its multi-omic platform for in vitro diagnosis and biomedical research. The company also appointed Dr Michael Risley as Chief Development Officer to support product commercialisation efforts.ZenopaSMi discloses £6 million seed funding round, bolsters team with new C-suite hireSMi Systems secured a £6 million seed funding round, comprising investments from Norcliffe Capital and Innovate UK grants, to advance its single-molecule imaging platform for biomedical diagnostics. The company simultaneously appointed Dr Michael Risley as Chief Development Officer to accelerate the commercialization of this technology for detecting biomarkers in diseases such as cancer and respiratory infections.IndianpharmapostSMi discloses £6 million seed funding round, bolsters team with new C-suite hireSMi Systems secured a £6 million seed funding round, comprising investments from Norcliffe Capital and Innovate UK grants, to develop its single-molecule imaging platform for biomedical diagnostics. To support the commercialization of this technology, the company appointed Dr Michael Risley as its new Chief Development Officer.Bio-EquipSMi Discloses ï¿¡6 Million Seed Funding Round, Bolsters Team with New C-suite HireSMi Systems secured £6 million in seed funding from Norcliffe Capital and Innovate UK grants to develop a multi-omic platform for disease detection and therapeutic discovery. The company also appointed Dr Michael Risley as Chief Development Officer to accelerate the commercialization of its single-molecule imaging technology.ClinicalresearchnewsonlineSMi discloses £6 million seed funding round, bolsters team with new C-suite hireSMi Systems secured a £6 million seed funding round led by Norcliffe Capital and supported by Innovate UK grants to develop a multi-omic diagnostic platform based on super-resolution imaging technology. To support this development, the company appointed Dr Michael Risley as Chief Development Officer to accelerate product commercialization. The funds will be used to prove the utility of the platform for detecting biomarkers in infectious diseases and cancer.